Secukinumab cut ankylosing spondylitis symptoms in MEASURE trials

Secukinumab, an interleukin 17-A inhibitor approved for the treatment of moderate to severe psoriasis, significantly reduced the signs and symptoms of ankylosing spondylitis in two phase III trials, researchers reported Dec. 23 in the New England Journal of Medicine. The results of the...
Source: Skin and Allergy News - Category: Dermatology Source Type: news